Company: STAA
Filing Date: 2025-09-16
Form Type: DEFM14A
Source: 0001193125-25-204396
Chunk: 108

Company: STAAR SURGICAL CO
Filing Date: 2025-09-16
Form: DEFM14A
Chunk 108
---
 to the Effective
Time at the target level and prorated based on the portion of the performance period that has elapsed through the Effective Time (with any entitlements to prorated bonus pursuant to change in control agreements reduced accordingly by such amounts
paid).

Indemnification Insurance

STAAR’s directors and executive officers will be entitled to certain ongoing indemnification and coverage for a period of not less than
six years following the Effective Time under directors’ and officers’ liability insurance policies from the Surviving Company. This indemnification and insurance coverage is further described in the section entitled “The Merger
Agreement—Indemnification and Insurance.”

New Compensation Arrangements

Any executive officers and directors who become officers, directors or employees or who otherwise are retained to provide services to the
Surviving Company may enter into new individualized compensation arrangements and may participate in cash or equity incentive or other benefit plans maintained by Alcon, any of its affiliates or the Surviving Company. As of the date of this proxy
statement, no compensation arrangements between such persons and the Surviving Company and/or its affiliates have been established or discussed.

Quantification of Payments and Benefits to STAAR’s Named Executive Officers

The table below sets forth the amount of payments and benefits that each of STAAR’s named executive officers would receive in connection
with the Merger, assuming (i) that the Merger were consummated and each such named executive officer experienced a termination without cause on August 27, 2025; and (ii) a per share price of STAAR common stock of $28.00, which is the
Merger Consideration. The calculations in the table below do not attempt to forecast any adjustments in compensation that may occur following the date of this proxy statement, including additional awards, grants or forfeitures that may occur prior
to the Effective Time or any awards that, by their terms, vest irrespective of the Merger prior to the Effective Time. As a result of the foregoing assumptions, which may or may not actually occur or be accurate on the relevant date, including the
assumptions described in the footnotes to the table, the actual amounts, if any, to be received by a named executive officer may materially differ from the amounts set forth below.

-64-

| Name                                         |     | Cash ($)(1) |           |     | Equity ($)(2) |            |     | Perquisites/ 
 Benefits     
 ($)(3)       |         |     | Tax           
 Reimbursement